Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment
Cancers · 17.07.2026 · 18 (14) · 2304
DOI: 10.3390/cancers18142304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.07.2026. Verfasst von Alanna Davis und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72212, USA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Drs. Martin and Dorothy Spatz Charitable Foundation, VA Merit Award.
Abstract (Originalsprache)
Background
Novel Sézary syndrome (SS) biomarker genes identified previously through transcription profiling were examined for changes in expression after mogamulizumab treatment. Incorporating new biomarkers for measuring response to disease would improve clinical care.
Objective
To assess novel SS biomarker and cytokine genes in patients treated with mogamulizumab with clinical response, blood response, and immunologic parameters.
Methods
We performed a real-world case–control and case–case study analyzing the expression of SS biomarker genes in peripheral blood mononuclear cells (PBMCs) from six SS patients treated with mogamulizumab using qRT-PCR.
Results
We demonstrated a reduced expression of SS biomarker genes in PBMCs of SS patients following mogamulizumab therapy. In our cohort, five of the SS biomarker genes (PLS3, TWIST1, KCNK1, DNM3 and TOX) showed statistically consistent high expression compared to normal PBMCs at baseline. After treatment with mogamalizumab, these five SS biomarkers showed significant correlations with skin response (p < 0.05) and three (TOX, TCRL3 and DNM3) with blood response (p < 0.05). A decrease in GATA3 expression correlated to an improvement in skin severity, and STAT4 inversely correlated to Sézary cell decrease (p < 0.05). Two cytokine genes, IL4 and IFNG, reflective of an immune response that is abnormal in SS, showed a trend to normalized expression with IL-4 decreasing and IFNG increasing after treatment.
Limitations
This was a real-world study of patients who failed prior treatments, with a small sample size and variable timing between patient sample collection.
Conclusions
Unique SS biomarker, cytokine and T cell transcription factor genes are valuable in assessing molecular and immune responses following treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72212, USA.
- Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Department of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Department of Dermatology, University of California, 3350 La Jolla Village Dr., San Diego, CA 92093, USA.
- Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR 72212, USA.
- Dermatology Service, Veterans Administration San Diego Health System, San Diego, CA 92161, USA.
ORCID-Profile: Ping-Ching Hsu, Henry K Wong
Förderung
- CSRD VA
- Drs. Martin and Dorothy Spatz Charitable Foundation
- VA Merit Award
Zitieren
APA
Davis, A., Ying, J., Hsu, P. C., Chen, J., Tran, K., & Wong, H. K. (2026). Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment. Cancers, 18(14), 2304. https://doi.org/10.3390/cancers18142304
Vancouver
Davis A, Ying J, Hsu PC, Chen J, Tran K, Wong HK. Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment. Cancers. 2026;18(14):2304. doi:10.3390/cancers18142304
BibTeX
@article{Davis2026,
author = {Davis, Alanna and Ying, Jun and Hsu, Ping-Ching and Chen, Jeffrey and Tran, Khiem and Wong, Henry K},
title = {Sézary Syndrome Biomarker, T Cell Transcription Factors and Cytokine Genes Provide Novel Insight into Response During Mogamulizumab Treatment},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2304},
doi = {10.3390/cancers18142304}
}
EUVIMED